A treatment can work and still be difficult to deliver. Consider cell therapy: living cells must be processed, handled and manufactured before they can become somebody’s medicine. The scientific discovery is only part of the job. In May 2021, Decheng Capital led an $82 million financing for Cellares, a company trying to automate that manufacturing. Eclipse Ventures co-led. The bet was on a practical question: what happens when promising biology meets a production line?
- Decheng backs life sciences and healthcare companies with capital and strategic support.
- Cellares makes its interest in the infrastructure behind medicine unusually concrete.
- Acquisitions, fund commitments and financing rounds measure different things. Keep the labels attached.
01 / The factory in the story
Cellares called its Cell Shuttle a factory-in-a-box. The system combined hardware, software, robotics and consumables to automate the laborious manufacture of individualized cell therapies. For an investor, that creates an interesting possibility: a business serving drug developers whose medicines may differ, but whose manufacturing headaches overlap. Decheng was financing a supplier to the scientific effort, alongside its investments in the science itself.
The money had a specific purpose: accelerate development of the platform. In August 2023, Cellares raised another $255 million, with Decheng participating, to launch its integrated development and manufacturing organization and Smart Factory. This was becoming a business that would operate manufacturing infrastructure, rather than simply develop a clever piece of equipment. Laboratories and factories ask different things of a balance sheet.
A customer supplied another kind of evidence. In April 2024, Bristol Myers Squibb and Cellares announced a $380 million capacity reservation and supply agreement for CAR T manufacturing. That agreement was separate from venture funding. It connected the automation proposition to a pharmaceutical company’s manufacturing plans. It also illustrated why a patient’s journey can depend on businesses far removed from the clinic.
02 / A scientist on both sides of the table
Decheng’s founder, Min Cui, trained in cancer biology at Stanford after studying molecular biology at Peking University. He started two biotech companies, then spent five years at Bay City Capital before founding Decheng. His biography describes someone who has occupied several seats around the same table: scientist, entrepreneur, investor and director. Those experiences help explain the firm’s emphasis on company building.
The portfolio widens the picture. Decheng groups its investments into biopharma, diagnostics and tools, medical devices, and services. Its stated remit includes early-stage life science companies and growth-stage healthcare businesses. It lists offices in Menlo Park and Shanghai. A founder seeking support is therefore approaching a healthcare specialist with a range of entry points, rather than a fund organized around one drug modality.
Specialization alone does not distinguish it from every alternative. OrbiMed also invests globally across healthcare, from startups to public companies, and offers private credit and royalty strategies. Decheng’s particular appeal is better judged through its people, board involvement and relevant investments. The useful comparison for an entrepreneur is concrete: who understands this experiment, this manufacturing problem, this next financing?
03 / Read the small label on the big number
An investment firm has two constituencies. Limited partners supply capital to its funds; portfolio companies receive investment and strategic support. Patients may eventually benefit from those companies’ work, but they are not buying Decheng’s investment service. Its business is allocating pooled capital and helping companies develop. That distinction matters when the impressive numbers begin to arrive.
Sold in a $700 million fund offering.
42 investors. A fund raise, not company revenue.
Decheng’s website reports more than $2.5 billion in assets under management. Separately, an October 2025 SEC amendment for Global Life Sciences Fund V reported $452 million sold against a $700 million offering, with 42 investors. Neither figure gives the management company a valuation. Nor does either tell a founder what check Decheng will write. Scale becomes informative only after you identify what is being counted.
Acquisition prices require the same discipline. In April 2024, Vertex agreed to acquire Decheng portfolio company Alpine Immune Sciences for approximately $4.9 billion in cash. That is a buyer’s price for a company, not Decheng’s proceeds. Another portfolio company, Mammoth Biosciences, announced a Regeneron collaboration involving $100 million at signing, including $95 million in equity investment. The headline number bundled different economic ingredients.
04 / The IPO badge has a sequel
Decheng’s portfolio page records Cue Health’s 2021 IPO. The next chapters are less cheerful. In May 2024, the FDA warned against using Cue’s COVID-19 tests because of an increased risk of false results, following unauthorized modifications. On May 28, Cue filed for Chapter 7 bankruptcy. The company said efforts to obtain financing or arrange a strategic transaction had not produced a solution.
That sequence resists a tidy explanation in which one bad event caused everything. It does show why an IPO cannot serve as the last line of a healthcare investment story. Reliability, regulatory obligations and financial survival remain operating requirements after the listing ceremony. A portfolio containing Alpine and Cue makes the uncertainty visible. The public milestones tell us what happened to companies; they do not establish the fund’s returns.
05 / Follow the constraint
By January 2026, Cellares had announced a $257 million Series D co-led by BlackRock-managed funds and Eclipse. In June, it expanded that round to $327 million. The growing capital requirement is part of the lesson. Manufacturing infrastructure takes sustained funding, and planned commercial operations still have to become operating reality.
“The barrier to curing more patients is no longer scientific - it is industrial.”Fabian Gerlinghaus · Cellares CEO · January 2026
Read that as a manufacturing company’s thesis, rather than a universal verdict on medicine. The useful habit to copy is narrower: identify the constraint that remains after an invention works. For a biotech founder, that might be production, delivery or repeatability. This approach needs enough demand, credible technology and capital that can survive long development cycles. Automation cannot rescue ineffective biology. Decheng’s Cellares investment makes that practical boundary worth examining.